Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-76fb5796d-vvkck Total loading time: 0 Render date: 2024-04-26T04:47:47.241Z Has data issue: false hasContentIssue false

Chapter 25 - Lessons learned: neuroprotective trials in Parkinson's disease

from Section IV - Clinical Trials in Parkinson's Diease: Lessons, Controversies and Challenges

Published online by Cambridge University Press:  05 March 2016

By
Isabelle Beaulieu-Boire  and
Anthony E. Lang
Edited by
Néstor Gálvez-Jiménez ,
Hubert H. Fernandez ,
Alberto J. Espay  and
Susan H. Fox
Néstor Gálvez-Jiménez
Affiliation:
Cleveland Clinic, Florida
Hubert H. Fernandez
Affiliation:
Cleveland Clinic, Ohio
Alberto J. Espay
Affiliation:
University of Cincinnati
Susan H. Fox
Affiliation:
Toronto Western Hospital
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Parkinson's Disease
Current and Future Therapeutics and Clinical Trials
 , pp. 265 - 279
Publisher: Cambridge University Press
Print publication year: 2016

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Lang, AE. Clinical trials of disease-modifying therapies for neurodegenerative diseases: the challenges and the future. Nat Med 2010; 16: 1223–6.Google Scholar
Stocchi, F, Olanow, CW. Obstacles to the development of a neuroprotective therapy for Parkinson's disease. Mov Disord 2013; 28: 3–7.CrossRefGoogle Scholar
Olanow, CW, Kieburtz, K, Schapira, AHV. Why have we failed to achieve neuroprotection in Parkinson's disease? Ann Neurol 2009; 64 (Suppl. 2): S101–10.CrossRefGoogle Scholar
Hirsch, EC. How to improve neuroprotection in Parkinson's disease? Parkinsonism Relat Disord 2007; 13 (Suppl. 3): S332–5.Google Scholar
D'Agostino, RB. The delayed-start study design. N Engl J Med 2009; 361: 1304–6.Google Scholar
Cheng, HC, Ulane, CM, Burke, RE. Clinical progression in Parkinson disease and the neurobiology of axons. Ann Neurol 2010; 67: 715–25.CrossRefGoogle ScholarPubMed
Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA 2000; 284: 1931–8.CrossRefGoogle Scholar
Fahn, S, Oakes, D, Shoulson, I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004; 351: 2498–508.Google Scholar
Whone, AL, Watts, RL, Stoessl, AJ, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 2003; 54: 93–101.CrossRefGoogle ScholarPubMed
Goetz, CG, Tilley, BC, Shaftman, SR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008; 23: 2129–70.CrossRefGoogle ScholarPubMed
Hauser, RA, Auinger, P, Parkinson Study Group. Determination of minimal clinically important change in early and advanced Parkinson's disease. Mov Disord 2011; 26: 813–8.CrossRefGoogle ScholarPubMed
Richards, M, Marder, K, Cote, L, Mayeux, R. Interrater reliability of the Unified Parkinson's Disease Rating Scale motor examination. Mov Disord 1994; 9: 89–91.CrossRefGoogle ScholarPubMed
Goetz, CG, Leurgans, S, Raman, R, Parkinson Study Group. Placebo-associated improvements in motor function: Comparison of subjective and objective sections of the UPDRS in early Parkinson's disease. Mov Disord 2002; 17: 283–8.Google Scholar
Parashos, SA, Swearingen, CJ, Biglan, KM, et al. Determinants of the timing of symptomatic treatment in early Parkinson disease: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) Experience. Arch Neurol 2009; 66: 1099–104.Google Scholar
Ravina, B, Camicioli, R, Como, PG, et al. The impact of depressive symptoms in early Parkinson disease. Neurology 2007; 69: 342–7.Google Scholar
Marras, C, McDermott, MP, Marek, K, et al. Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts. Mov Disord 2011; 26: 608–13.Google Scholar
Agarwal, PA, Stoessl, AJ. Biomarkers for trials of neuroprotection in Parkinson's disease. Mov Disord 2012; 28: 71–85.Google Scholar
Pavese, N, Kiferle, L, Piccini, P. Neuroprotection and imaging studies in Parkinson's disease. Parkinsonism Relat Disord 2009; 15 (Suppl. 4): S33–7.Google Scholar
Ravina, B, Eidelberg, D, Ahlskog, JE, et al. The role of radiotracer imaging in Parkinson disease. Neurology 2005; 64: 208–15.Google Scholar
Snow, BJ, Tooyama, I, McGeer, EG, et al. Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels. Ann Neurol 1993; 34: 324–30.CrossRefGoogle ScholarPubMed
Nandhagopal, R, Kuramoto, L, Schulzer, M, et al. Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography study. Brain. 2009; 132: 2970–9.CrossRefGoogle ScholarPubMed
Vingerhoets, FJ, Schulzer, M, Calne, DB, Snow, BJ. Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion? Ann Neurol 1997; 41: 58–64.CrossRefGoogle ScholarPubMed
Pirker, W. Correlation of dopamine transporter imaging with parkinsonian motor handicap: how close is it? Mov Disord 2003; 18: S43–51.Google Scholar
Martin, WRW, Wieler, M, Stoessl, AJ, Schulzer, M. Dihydrotetrabenazine positron emission tomography imaging in early, untreated Parkinson's disease. Ann Neurol 2008; 63: 388–94.Google Scholar
Morrish, PK. How valid is dopamine transporter imaging as a surrogate marker in research trials in Parkinson's disease? Mov Disord 2003; 18 (Suppl. 7): S63–70.Google Scholar
Parkinson Study Group. A randomized controlled trial comparing pramipexole with levodopa in early Parkinson's disease: design and methods of the CALM-PD Study. Clin Neuropharmacol 2000; 23: 34–44.CrossRefGoogle Scholar
Winogrodzka, A, Booij, J, Wolters, EC. Disease-related and drug-induced changes in dopamine transporter expression might undermine the reliability of imaging studies of disease progression in Parkinson's disease. Parkinsonism Relat Disord 2005; 11: 475–84.CrossRefGoogle ScholarPubMed
Eckert, T, Eidelberg, D. Neuroimaging and therapeutics in movement disorders. NeuroRx 2005; 2: 361–71.Google Scholar
Eckert, T, Tang, C, Eidelberg, D. Assessment of the progression of Parkinson's disease: a metabolic network approach. Lancet Neurol 2007; 6: 926–32.Google Scholar
Vaillancourt, DE, Spraker, MB, Prodoehl, J, et al. High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease. Neurology 2009; 72: 1378–84.Google Scholar
Berg, D. Transcranial ultrasound as a risk marker for Parkinson's disease. Mov Disord 2009; 24 (Suppl. 2): S677–83.Google Scholar
Sperling, RA, Aisen, PS, Beckett, LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 280–92.Google Scholar
Lang, AE, Melamed, E, Poewe, W, Rascol, O. Trial designs used to study neuroprotective therapy in Parkinson's disease. Mov Disord 2012; 28: 86–95.CrossRefGoogle ScholarPubMed
Olanow, CW, Rascol, O, Hauser, R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009; 361: 1268–78.Google Scholar
Clarke, CE. Are delayed-start design trials to show neuroprotection in Parkinson's disease fundamentally flawed? Mov Disord 2008; 23: 784–9.CrossRefGoogle ScholarPubMed
Ahlskog, JE, Uitti, RJ. Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction? Neurology 2010; 74: 1143–8.Google Scholar
Schwid, SR, Cutter, GR. Futility studies: spending a little to save a lot. Neurology 2006; 66: 626–7.Google Scholar
Bezard, E, Yue, Z, Kirik, D, Spillantini, MG. Animal models of Parkinson's disease: Limits and relevance to neuroprotection studies. Mov Disord 2012; 28: 61–70.CrossRefGoogle ScholarPubMed
Schober, A. Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. Cell Tissue Res 2004; J318: 215–24.Google Scholar
Luk, KC, Kehm, V, Carroll, J, et al. Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 2012; 338: 949–53.Google Scholar
Olanow, CW, Brundin, P. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder? Mov Disord 2013; 28: 31–40.Google Scholar
Lim, KL, Ng, CH. Genetic models of Parkinson disease. Biochim Biophys Acta 2009; 1792: 604–15.Google Scholar
AlDakheel, A, Kalia, LV, Lang, AE. Pathogenesis-targeted, disease-modifying therapies in Parkinson disease. Neurotherapeutics 2013; 11: 6–23.Google Scholar
Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989; 321: 1364–71.Google Scholar
Olanow, CW, Hauser, RA, Gauger, L, et al. The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol 1995; 38: 771–7.Google Scholar
Negrotti, A, Bizzarri, G, Calzetti, S. Long-term persistence of symptomatic effect of selegiline in Parkinson's disease. A two-months placebo-controlled withdrawal study. J Neural Transm 2001; 108: 215–19.Google Scholar
Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 2002; 59: 1937–43.CrossRefGoogle Scholar
Clarke, CE, Patel, S, Ives, N, et al. Should treatment for Parkinson's disease start immediately on diagnosis or delayed until functional disability develops? Mov Disord 2011; 26: 1187–93.CrossRefGoogle ScholarPubMed
de la Fuente-Fernández, R, Schulzer, M, Mak, E, Sossi, V. Parkinsonism and related disorders. Parkinsonism Relat Disord 2010; 16: 365–9.Google Scholar
Schwarzschild, MA. Rasagiline in Parkinson's disease. N Engl J Med 2010; 362: 658; author reply 658–9.Google Scholar
Fahn, S. Is levodopa toxic? Neurology 1996; 47 (Suppl. 3): S184–95.Google Scholar
Jenner, PG, Brin, MF. Levodopa neurotoxicity: experimental studies versus clinical relevance. Neurology 1998; 50 (Suppl. 6): S39–48.Google Scholar
Hauser, RA, Holford, NHG. Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's disease. Mov Disord 2002; 17: 961–8.Google Scholar
LEAP Study Protocol. Levodopa in early Parkinson's disease: the LEAP study. Availabe at: http://leapamc.nl/wp-content/uploads/2011-12-22-Onderzoeksprotocol.pdf.Google Scholar
Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002; 287: 1653–61.Google Scholar
Parkinson Study Group, CALM Cohort Investigators. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Arch Neurol 2009; 66: 563–70.Google Scholar
Schapira, AHV, Albrecht, S, Barone, P, et al. Rationale for delayed-start study of pramipexole in Parkinson's disease: the PROUD study. Mov Disord 2010; 25: 1627–32.Google Scholar
Schapira, AHV, McDermott, MP, Barone, P, et al. Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial. Lancet Neurol 2013; 12: 747–55.Google Scholar
NINDS NET-PD Investigators. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 2006; 66: 664–71.Google Scholar
NET-PD. Study News. Statement on the Termination of NET-PD LS-1 Study. Available at: http://parkinsontrial.ninds.nih.gov/netpd-LS1-study-termination.htm.Google Scholar
Parkinson Study Group PRECEPT Investigators. Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. Neurology 2007; 69: 1480–90.CrossRefGoogle Scholar
Olanow, CW, Schapira, AHV, LeWitt, PA, et al. TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol 2006; 5: 1013–20.Google Scholar
Nutt, JG, Burchiel, KJ, Comella, CL, et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 2003; 60: 69–73.Google Scholar
Lang, AE, Gill, S, Patel, NK, et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 2006; 59: 459–66.Google Scholar
Marks, WJ, Bartus, RT, Siffert, J, et al. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol 2010; 9: 1164–72.Google Scholar
Bartus, RT, Baumann, TL, Siffert, J, et al. Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients. Neurology 2013; 80: 1698–701.Google Scholar
PR Newswire. Ceregene reports data from Parkinson's disease phase 2b study. Available at: http://www.prnewswire.com/news-releases/ceregene-reports-data-from-parkinsons-disease-phase-2b-study-203803541.html.Google Scholar
Kordower, JH, Olanow, CW, Dodiya, HB, et al. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain 2013; 136: 2419–31.Google Scholar
Liu, J, Wang, L, Zhan, SY, Xia, Y. Coenzyme Q10 for Parkinson's disease. Cochrane Database Syst Rev 2011; (12): CD008150.Google Scholar
National Institute of Neurological Disorders and Stroke. Statement on Termination of QE3 Study. Available at: http://www.ninds.nih.gov/disorders/clinical_trials/CoQ10-Trial-Update.htm.Google Scholar
Snow, BJ, Rolfe, FL, Lockhart, MM, et al. A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease. Mov Disord 2010; 25: 1670–4.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×